$ cat ./records/gates-reportedly-steered-oxford-away-from-an-open-license-covid-v-2020.txt
Gates Reportedly Steered Oxford Away From an Open-License COVID Vaccine to a Deal With AstraZeneca
[RECORD.TXT] · cat --full
Early in the pandemic, Oxford University researchers signaled they would offer their COVID-19 vaccine on a nonexclusive, royalty-free basis so any manufacturer could produce it cheaply. In May 2020 Oxford reversed course and signed an exclusive deal with the drugmaker AstraZeneca. Reporting by Kaiser Health News and others said the shift followed the Gates Foundation urging Oxford to partner with a major pharmaceutical company; Gates publicly recounted telling Oxford it 'really need[ed] to team up.' AstraZeneca pledged to sell at cost during the pandemic, and the vaccine became one of the most widely used in lower-income countries, but critics argued the exclusive arrangement surrendered public control over pricing and supply and squandered a chance to 'change the economics of vaccine development.'
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Vaccine-Derived Polio Cases Outnumber Wild Polio, Complicating the Gates-Backed Eradication Drive
Next →
'False Promises' Report Says the Gates-Funded Green Revolution in Africa Failed Its Goals
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.